Santen Pharmaceutical Co (Santen Pharmaceutical Co) Total Liabilities : $902 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Total Liabilities?

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 was $902 Mil.

Santen Pharmaceutical Co's quarterly Total Liabilities declined from Jun. 2023 ($822.80 Mil) to Sep. 2023 ($815.25 Mil) but then increased from Sep. 2023 ($815.25 Mil) to Dec. 2023 ($901.76 Mil).

Santen Pharmaceutical Co's annual Total Liabilities increased from Mar. 2021 ($879.85 Mil) to Mar. 2022 ($1,038.41 Mil) but then declined from Mar. 2022 ($1,038.41 Mil) to Mar. 2023 ($956.74 Mil).

Santen Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Santen Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Total Liabilities Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

887.26

986.45

879.85

1,038.41

956.74

Santen Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															888.54	956.74	822.80	815.25	901.76

Santen Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Santen Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	669.618	+	(0	+	277.613
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	9.509)
	=	957

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	3151.021	-	2194.281
	=	957

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	635.068	+	(0	+	257.095
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	9.592)
	=	902

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	2971.354	-	2069.599
	=	902

Santen Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020